PRESS RELEASE

MolMed: Calendar of corporate events for fiscal year 2019

Milan (Italy), January 28th 2019 – MolMed S.p.A. (MLMD.MI), clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases, announces the calendar of corporate events for fiscal year 2019.

The calendar is available on MolMed's website (www.molmed.com). Any amendments will be promptly communicated to the market.

Board of Directors

DATE	SUBJECT
18 March 2019	Approval of draft statutory financial statements for FY 2018
13 May 2019	Approval of interim financial report at 31/03/2019 (*)
29 July 2019	Approval of half-year financial report at 30/06/2019
11 November 2019	Approval of interim financial report at 30/09/2019 (*)

(*) additional interim financial information

Shareholders' Meetings

DATE	SUBJECT
30 April 2019	Approval of statutory financial statements for FY 2018

Under the regulations in force[1] and in order to ensure continuity with the past, MolMed decided to continue the publication of quarterly reports as additional interim financial information ("Additional Info"), on a voluntary basis and until otherwise decided, as already done during fiscal year 2016, 2017 and 2018 with the same form and content to those of the previous fiscal years.

The Additional Info will be subject to approval by the Board of Directors (the "Board") in meetings to be held within 45 days from the end of the first and third quarter of each fiscal year, and will be disclosed to the market with the same timing, by means of:

- issuance of a press release upon the conclusion of the Board meeting approving the interim financial information;
- publication of the Additional Info on the corporate website (www.molmed.com) within the section devoted to financial reports.

1 Italian Legislative Decree n. 25/2016 implementing Directive 2013/50/EU (the "Decree") eliminated the mandatory requirement to publish the quarterly interim financial reports, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998 (the "TUF"). The Decree also granted to Consob the powers of providing for any additional disclosure requirements beyond the annual and halfyear financial statements. On the basis of the powers granted by the Decree, Consob - by way of resolution n. 19770 of October 26, 2016 - introduced some amendments to the Issuers' Regulation concerning additional interim financial information (new Article 82-ter), in force from January 2, 2017.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, is looking forward to obtain the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
+39 02 21277.205
+39 02 21277.325
investor.relations@molmed.com